MustGrow Biologics Corp. (MGRO:CA) Q2 2026 Earnings Name Transcript

Operator

Welcome to MustGrow Biologics Q2 2026 Earnings Name with CEO, Corey Giasson; and COO, Colin Bletsky. The monetary statements and administration dialogue and evaluation can be found on SEDAR+. As we speak’s remarks could include forward-looking statements. These statements contain recognized and unknown dangers and uncertainties. Please consult with MustGrow’s filings on SEDAR+ for extra info. After administration’s remarks, we’ll open the decision for questions. [Operator Instructions] Welcome, gents, and please start your presentation.

Corey Giasson
President, CEO & Director

Thanks, Martin. Good afternoon, everybody, and welcome to MustGrow’s Q2 2026 Earnings Name and question-and-answer session. Earlier than I start, I would like to attract your consideration to our disclaimer. Ahead-looking statements are going to be made on this presentation and the Q&A session on the finish. Once more, a few of these statements is not going to come to fruition. This disclaimer will be learn on our web site at mustgrow.ca.

So final week, we introduced the Q2 2026 outcomes. TerraSante gross sales income for the quarter was $75,000. Gross revenue — gross loss unfavourable margin of about $17,000. That was attributable to us transport product from Asia via air freight into the U.S., and it is fairly pricey. As you’ll be able to see, licensing income, we have been capable of report in Q2 that we had earned licensing income of about $1.4 million, and we made the announcement a few weeks in the past that we acquired that portion of the money. So within the Q2 monetary statements, it reads as an accounts receivable.

Our bills proceed to normalize with out NexusBioAg with about $900,000 quarterly of bills. And web revenue, which incorporates the discontinued operations of NexusBioAg, we had a revenue of about $300,000 versus